Pfizer Shares Data for First-of-its-Kind NSCLC Drug Targeting EML4-ALK Mutations in Cancer Cells
June 03, 2009
Pfizer Shares Data for First-of-its-Kind NSCLC Drug Targeting EML4-ALK Mutations in Cancer Cells
The drug "is the first agent in clinical development that selectively targets a unique genetic feature of cancer cells," Pfizer said in a statement released at ASCO's annual meeting here this week.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genetic Alliance, NCHPEG Team on Curriculum to Prep Docs for Genomic Medicine
May 23, 2013 / GenomeWeb Daily News - Roche Unveils Higher-Throughput Cobas Systems as it Maps out MDx Strategy
May 23, 2013 / PCR Insider - Studies Indicate Effectiveness of New LAMP-based Malaria Test in Modern Labs, Endemic Countries
May 23, 2013 / PCR Insider - Wave 80 Aims to Begin Clinical Trials this Year for POC MDx System, HIV Viral Load Assay
May 23, 2013 / PCR Insider - Brazil Plans $680M for Research Institutes; Includes Genomics Center
May 23, 2013 / GenomeWeb Daily News